Novel tests improve diagnosis of two types of liver cancer

Share this article:

New data from two clinical trials that were presented at the International Liver Congress 2013 in Amsterdam, the Netherlands, demonstrated substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma using diagnostic urine tests.

HCC is common throughout the world and most often develops as a late complication of chronic viral hepatitis or cirrhosis of any cause. Because the overall survival rate of HCC is poor, screening for HCC offers the best hope for early detection, eligibility for treatment, and improved survival. While effective therapies exist, the available screening tests to detect HCC, which are alpha-fetoprotein (AFP) and ultrasound, are reported to have low sensitivity and specificity (50%–85% and 70%–90%, respectively).

Preliminary data demonstrate the performance of urinary metabolites in helping to diagnose HCC. Urine samples were collected from four subject groups in West Africa on the case-control platform of PROLIFICA 'Prevention of Liver Fibrosis and Carcinoma in Africa' as follows: patients with HCC (n=65), cirrhosis (n=36), noncirrhotic liver disease (n=110), and healthy controls (n=91). HCC patients were diagnosed using guidelines from the European Association for the Study of the Liver (EASL).

Multivariate analyses of urinary nuclear magnetic resonance (NMR) spectra showed a distinct profile for urine of patients with HCC compared to the other conditions, and the urinary metabolite profile outperformed serum AFP.

"These findings will be welcomed by physicians as they validate urinary metabolic profiling as a potential screening tool for HCC, with superior diagnostic accuracy to serum AFP and, if investigated further and put into practice, this noninvasive technique could simplify and improve clinical diagnosis and outcomes for patients," said Mark Thursz, MD, Secretary General of EASL.

Similarly, detection of cholangiocarcinoma remains a diagnostic challenge and physicians will be encouraged by results from a Phase II study showing that a combined bile and urine proteomic test increased diagnostic accuracy of cholangiocarcinoma in patients with biliary strictures (an abnormal narrowing of the common bile duct) of unknown origin.

Researchers recently established diagnostic peptide marker models in bile and urine to detect both local and systemic changes during cholangiocarcinoma progression, and so they combined both models with the aim of reaching a higher diagnostic accuracy.

The data demonstrated this model enables impressive cholangiocarcinoma diagnosis with an accuracy of more than 90% that is most applicable for patients with biliary strictures of unknown origin referred to endoscopy.

Thursz added, "These important findings substantially improve the diagnosis of [cholangiocarcinoma] and may lead to early therapy and improved prognosis. Overall both data sets demonstrate the increasing value of proteomic and metabonomic techniques and if confirmed by further investigation, clinicians may soon be using simple urine dip-stick tests to diagnose HCC and [cholangiocarcinoma]."

Cholangiocarcinoma or bile duct cancer is rare and almost always adenocarcinoma which starts in the lining of the bile duct. The cause of most cholangiocarcinomas is unknown but people with chronic inflammatory bowel conditions or congenital abnormalities of the bile duct have a higher risk of developing the cancer.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Support team aids decision-making by caregivers of terminal cancer patients

Researchers devised an intervention that quickly integrates a cancer support team to guide caregivers and their patients through difficult end-of-life treatment and decisions.

Protein inhibition opens door for pancreatic cancer treatment

The protein galectin-1 has been identified as a possible therapeutic target for pancreatic cancer; new research has demonstrated that inhibiting this protein in mice with pancreatic cancer increased survival by 20%.

Noninvasive advanced image analysis may improve care for lung cancer patients

Lung cancer patients could receive more precise treatment, and their progress could be better tracked by using a new high-tech method of non-invasive medical imaging analysis, according to a new study.